Pfizer "Disappointed" About 1st Instance Decision By Opposition Division Of European Patent Office To Maintain Moderna's European Patent Ep3590949 B1; Says Will Consider All Legal Options And May Appeal Decision By European Patent Office
Portfolio Pulse from Benzinga Newsdesk
Pfizer expressed disappointment over the European Patent Office's decision to maintain Moderna's European Patent EP3590949 B1. Pfizer is considering all legal options and may appeal the decision.
May 17, 2024 | 5:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer is disappointed with the European Patent Office's decision to maintain Moderna's European Patent EP3590949 B1. Pfizer is considering all legal options and may appeal the decision.
The decision by the European Patent Office to maintain Moderna's patent could limit Pfizer's competitive edge in the market. The potential legal battle and uncertainty may negatively impact Pfizer's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100